Icorvida SR 1.5mg Prolonged-release Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

icorvida sr 1.5mg prolonged-release tablets

krka, d.d., novo mesto - indapamide - prolonged-release tablet - 1.5 milligram(s) - sulfonamides, plain; indapamide

Natrilix SR 1.5 mg, prolonged-release film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

natrilix sr 1.5 mg, prolonged-release film-coated tablets

les laboratoires servier - indapamide - prolonged-release tablet - 1.5 milligram(s) - sulfonamides, plain; indapamide

NATRILIX SR 1.5mg prolonged-release film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

natrilix sr 1.5mg prolonged-release film-coated tablets

imbat limited - indapamide - prolonged-release tablet - 1.5 milligram(s) - sulfonamides, plain; indapamide

Diurelix XL 1.5mg Prolonged-release Tablets Malta - English - Medicines Authority

diurelix xl 1.5mg prolonged-release tablets

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - indapamide - prolonged-release tablet - indapamide 1.5 mg - diuretics

APO-CHLORTHALIDONE TABLET Canada - English - Health Canada

apo-chlorthalidone tablet

apotex inc - chlorthalidone - tablet - 50mg - chlorthalidone 50mg - thiazide-like diuretics

SULFAMETHOXAZOLE AND TRIMETHOPRIM tablet United States - English - NLM (National Library of Medicine)

sulfamethoxazole and trimethoprim tablet

remedyrepack inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a sing